國家衛生研究院 NHRI:Item 3990099045/7946
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 858930      線上人數 : 70
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7946


    題名: Characterization of the clinical, biological, and therapeutic relevance of EZH2 overexpression in myxofibrosarcoma
    作者: Li, CF;Huang, HY
    貢獻者: National Institute of Cancer Research
    摘要: Background: Myxofi brosarcoma is genetically complex and insuffi ciently characterized in molecular determinants of clinical aggressiveness. By reappraising the public transcriptome (GSE21122), EZH2 was identifi ed as a top-ranking differentially upregulated gene among those regulating chromatin organization (GO:0006325) in myxofi brosarcoma tissues.Design: To validate the pathogenetic role of EZH2 in myxofi brosarcoma, mRNA abundance and protein expression of EZH2 were determined in independent samples by branched-chain DNA (bDNA) and immunohistochemical assays, yielding 40 and 87 informative cases, respectively. In vitro, RNA interference and DZNep treatment (targeting EZH2 associated PRC2 complex) were applied in EZH2-expressing myxofi brosarcoma cell lines to evaluate for the biological functions and therapeutic relevance of EZH2. The in vivo effect of DZNep treatment was examined in xenograft models established from two myxofi brosarcoma cell lines.Results: EZH2 protein overexpression was associated with higher histological grade (p=0.002), worse disease-specifi c and metastasis-free survival (both p£0.0001), and mRNA upregulation (p=0.010). In all myxofi brosarcoma cell lines, stable EZH2 knockdown resulted in impaired cell proliferative, migratory, and invasive capabilities with concomitant reductions in anchorage-independent colony formation and well-formed endothelial tubes. In vitro, DZNep caused dose- and time-dependent cytotoxicity and downregulated PRC2-associated proteins with induction of cellular apoptosis and attenuation of EZH2 promoter transactivity. The dose-dependent therapeutic effi cacy of DZNep was further corroborated in vivo in both xenograft myxofi brosarcoma models.Conclusions: EZH2 overexpression plays an oncogenic role in myxofi brosarcoma pathogenesis and promotes tumor growth, migration/invasion, and angiogenesis, hence conferring clinical aggressiveness and representing a novel therapeutic target of DZNep therapy.
    日期: 2014-02
    關聯: Modern Pathology. 2014 Feb;27(Suppl. 2):22A.
    Link to: http://dx.doi.org/10.1038/modpathol.2014.6
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0893-3952&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000331502200075
    顯示於類別:[其他] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000331502200075.pdf131KbAdobe PDF598檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋